JW Therapeutics: China's NMPA approves JW Therapeutics CAR-T cell therapy for mantle cell lymphoma

China's National Medical Products Administration (NMPA) has approved the supplemental Biological License Application (sBLA) for JW Therapeutics' Carteyva for relapsed or refractory mantle cell lymphoma (r/r MCL) in adults. The post China's NMPA approves JW Therapeutics CAR-T cell therapy for mantle cell lymphoma appeared first on Clinical Trials Arena.